נקסיום טבליות 40 מג

국가: 이스라엘

언어: 히브리어

출처: Ministry of Health

유효 성분:

ESOMEPRAZOLE

제공처:

ASTRAZENECA (ISRAEL) LTD

ATC 코드:

A02BC05

약제 형태:

טבליה

구성:

ESOMEPRAZOLE 40 MG

관리 경로:

פומי

처방전 유형:

מרשם נדרש

Manufactured by:

ASTRA ZENECA AB., SWEDEN

치료 그룹:

ESOMEPRAZOLE

치료 영역:

ESOMEPRAZOLE

치료 징후:

Nexium tablets are indicated for: Gastroesophageal reflux disease (GERD): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD). In combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylory associated ulcers. - Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk.Prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

승인 날짜:

2011-05-31

환자 정보 전단

Page 1 of 7
1986 – " )
(

20
"
:
20
"
)
(
esomeprazole 20 mg
as magnesium trihydrate)
)

40
"
:
40
"
)
(
esomeprazole 40 mg
as magnesium trihydrate)
)
:
2
"
"
6
."
" .
.
.
,
.
.
.
1
.
? ,
20
"
-
40 "
:
•
.
.
•
(
_Helicobacter pylori_
.)
,
.
•
(
NSAIDs
,)
.)
(
•
,
(
NSAIDs
)
,
.)
(
•
,
. ,
20
"
:
•
.
.
•
(
_Helicobacter_ _pylori_
.)
,
. ,
40
"
:
•
.
.
:
.)
(
2
.
:
•
(
6
.)"
"
•
)
(
(
,
,
,
.)
•
(
-
HIV
.)
Page 2 of 7
:
•
.
•
.
•
.
•
(
Chromogranin A
)
.
. , ,
:
•
•
•
•
)
(
(
,)
.
,
,
,
.
(
)
(
)
.
,
,
.
,
,
.
(
4
.)
.)
(
,
,
,
,
.
.
)
(
,
.
12
.
/ , , ,
.
(
-
HIV
.)
:
•
(
-
HIV
)
•
)
(
•
,
)
(
•
)
(
•
,
)
(
•
,
(
)
•
(
)
.
,
•
•
(
–
)
Page 3 of 7
•
)
(
•
)
)
•
(
.)
,
•
)
(
•
(
)
•
)
( '
)
)
)
(
,
.
.
,
,
.
.
,
.
.
,
.
(
4
)
.
.
,
)
(
.
-
,
.
-
1
(
23
."
"
)"
3
.
?
.
.
.
•
,)
(
.
•
.
,
.)
(
,
.
:
18
:
•
,
40
"
4
.
4
.
•
20
.
"
•
,
20
.
"
,
,
20
.
"
•
.
,
:
•
20
.
"
•
,
,
.
NSAIDS
:)
(
•
20
"
4
8
.
Page 4 of 7
NSAIDS
:)
(
•
20
.
"
-
:
•
40
"
4
.
12
:
•
,
40
"
4
.
4
.
•
20
"
.
•
,
20
.
"
•
.
,
:
•
20
"
.
•
.
,
,
•
.
•
.
•
.
.
(
pellets
coated
)
.
.
•
,
(
.)
(
.)
30
.
.
.
–
.
•
,
.
.
.
.
,
.
,
.
,
,
.
. ! .
.
. ,
4
.
.
,
.
.
:
Page 5 of 7
•
,
.
1,000
.
•
,
,
,
,
–
.
1,000
.
•
.
,
,
,
.
.
)
(
ת
ת ,רפ
ל
ת ר
-
,
'
רפ
.
10,000
.
-
10
•
•
:
,
,
,
•
•
-
100
•
•
(
)
•
,
(
"
)"
,
•
)
(
•
•
•
)
(
,
•
,
(
)
-
1,000
•
–
,
,
•
–
,
•
,
,
•
•
•
(
)
•
•
•
,
,
•
•
•
•
•
-
10,000
•
,
)
(
•
•
,
(
)
•
,
Page 6 of 7
•
.
,
,
(
-
,
'
,
)
•
•
•
(
)
•
:
,
.
,
,
,
,
.
.
.
.
•
)
(
•
,
.
,
,
)
(
.
.
, ,
. ,
"
(
"
www.health.gov.il
)
,
:
https://sideeffects.health.gov.il
5 .
?
•
!
.
/
.
•
(
(exp. date
.
.
:
•
C
°
25
.
6
.
:
Microcrystalline cellulose, methacrylic acid ethyl acrylate copolymer
(1:1), sugar
spheres, hypromellose, talc, triethyl citrate, hyprolose,
crospovidone, macrogol,
titanium dioxide (E 171), glycerol mon